Scott Carney Investigates Exposing the Regenerative Medicine Scam: Stem Cells, Peptides, Exosomes, and Fake Science
Apr 8, 2026
Matt Kaeberlein, a University of Washington biogerontologist who studies aging, walks through regenerative medicine, stem cells, peptides, and exosomes. He contrasts lab promise with real-world risks and stalled human results. He calls out hype, unregulated clinics, black-market stem products, and regulatory gaps. He outlines cautious pathways for safer, evidence-based progress.
AI Snips
Chapters
Transcript
Episode notes
Muse Cells Are Promising But Early
- Muse stem cells (Dezawa) are a biologically important subset of mesenchymal cells: stress-resistant, more pluripotent, and lower teratoma risk.
- They received conditional approval in Japan for safety but lack robust human efficacy data yet.
Unregulated Biologics Enable Dangerous Counterfeits
- Outside regulated environments product identity, purity, and sterility for stem cells and peptides are often unverifiable, raising contamination and impurity risks.
- Kaeberlein notes testing metformin is simple, but authenticating stem cell types requires specialized labs, enabling black markets.
Policy Steps To Test And Safely Expand Access
- Pursue policy solutions: fund NIH trials for experimental therapies and create regulated state-level 'right-to-try' pathways with IRB oversight and manufacturing safeguards.
- Kaeberlein proposes reallocating NIH funds to test top candidates and regulated access models as middle-ground solutions.